Literature DB >> 23710803

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

N Saljoughian1, F Zahedifard, D Doroud, F Doustdari, M Vasei, B Papadopoulou, S Rafati.   

Abstract

The use of an appropriate delivery system has recently emerged as a promising approach for the development of effective vaccination against visceral leishmaniasis (VL). Here, we compare two vaccine delivery systems, namely electroporation and cationic solid-lipid nanoparticle (cSLN) formulation, to administer a DNA vaccine harbouring the L. donovani A2 antigen along with L. infantum cysteine proteinases [CPA and CPB without its unusual C-terminal extension (CPB(-CTE) )] and evaluate their potential against L. infantum challenge. Prime-boost administration of the pcDNA-A2-CPA-CPB(-CTE) delivered by either electroporation or cSLN formulation protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-γ and lower levels of IL-10 production, leading to a strong Th1 immune response. At all time points, the ratio of IFN-γ: IL-10 induced upon restimulation with rA2-rCPA-rCPB and F/T antigens was significantly higher in vaccinated animals. Moreover, Th2-efficient protection was elicited through a high humoral immune response. Nitric oxide production, parasite burden and histopathological analysis were also in concordance with other findings. Overall, these data indicate that similar to the electroporation delivery system, cSLNs as a nanoscale vehicle of Leishmania antigens could improve immune response, hence indicating the promise of these strategies against visceral leishmaniasis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  DNA vaccination; cationic solid-lipid nanoparticles; delivery systems; electroporation; mice model; visceral leishmaniasis

Mesh:

Substances:

Year:  2013        PMID: 23710803     DOI: 10.1111/pim.12042

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

1.  Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary Study.

Authors:  Yasaman Taslimi; Farnaz Zahedifard; Tahereh Taheri; Delaram Doroud; Sakineh Latif Dizaji; Noushin Saljoughian; Sima Rafati
Journal:  Iran J Parasitol       Date:  2020 Jul-Sep       Impact factor: 1.012

Review 2.  Leishmaniasis in humans: drug or vaccine therapy?

Authors:  Masoud Ghorbani; Ramin Farhoudi
Journal:  Drug Des Devel Ther       Date:  2017-12-22       Impact factor: 4.162

Review 3.  Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges.

Authors:  Kiran Saleem; Zainab Khursheed; Christophe Hano; Iram Anjum; Sumaira Anjum
Journal:  Nanomaterials (Basel)       Date:  2019-12-09       Impact factor: 5.076

4.  DNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice.

Authors:  Gajadhar Bhakta; Victor Nurcombe; Amarnath Maitra; Anju Shrivastava
Journal:  Results Immunol       Date:  2014-04-18

Review 5.  Immunomodulation of nanoparticles in nanomedicine applications.

Authors:  Qing Jiao; Liwen Li; Qingxin Mu; Qiu Zhang
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

Review 6.  Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems.

Authors:  Vijay Mishra; Kuldeep K Bansal; Asit Verma; Nishika Yadav; Sourav Thakur; Kalvatala Sudhakar; Jessica M Rosenholm
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

7.  Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.

Authors:  M B Borgoyakova; L I Karpenko; A P Rudometov; D V Shanshin; A A Isaeva; V S Nesmeyanova; N V Volkova; S V Belenkaya; D E Murashkin; D N Shcherbakov; E A Volosnikova; E V Starostina; L A Orlova; N V Danilchenko; A V Zaikovskaya; O V Pyankov; A A Ilyichev
Journal:  Mol Biol       Date:  2021-12-17       Impact factor: 1.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.